As of July 2021, 16 states and Washington DC permit pharmacist prescribing of hormonal contraceptives. The objective of this systematic review is to describe the impact of pharmacist prescribing on hormonal contraceptive access in the United States (U.S.). Using a protocol based on PRISMA guidelines, a librarian performed the literature search for articles published between January 1, 2013 and January 15, 2021. Studies were excluded if they were incomplete (ie, without results) or the full text was not available. Studies that took place outside of the U.S., within the U.S. but in a state that had not implemented pharmacist contraception prescribing at the time the research was initiated, or not written in English, as well as those that were not primary literature (ie, reviews, editorials, opinion papers, etc.) were also excluded from this review. Articles were categorized based on whether the outcomes evaluated (a) uptake of pharmacist-prescribed hormonal contraceptive services, (b) implementation of pharmacist-prescribed hormonal contraceptive services, or (c) impact of pharmacist-prescribed hormonal contraceptive services on patients' access to hormonal contraception. Of 2056 identified articles, 21 articles met the inclusion criteria and were included in the analysis. The majority (n = 16) assessed uptake of the service, whereas eight examined implementation and three evaluated impact of the service on patients' access. More research is warranted on the impact of pharmacist prescribing on patients' access to hormonal contraceptives.